The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. 2005

Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
Prague Psychiatric Center affiliated with the Charles University 3rd Faculty of Medicine and the Center of Neuropsychiatric Studies, 181 03 Prague 8, Czech Republic. bubenikova@pcp.lf3.cuni.cz

Dizocilpine (MK-801; 0.3 mg/kg i.p.)-induced disruption in prepulse inhibition of the acoustic startle response (PPI) can be preferentially restored by "atypical" antipsychotics. In contrast, some findings indicate that not all of the "atypical" antipsychotics, such as clozapine and risperidone, are effective in restoring the NMDA antagonist-induced deficits in PPI. In our study, we evaluated the effect of four different "atypical" antipsychotic drugs on deficits in PPI induced by MK-801. Zotepine and risperidone have high affinities to D2-like and 5-HT2A receptors, while clozapine and olanzapine have multipharmacological profiles with the highest affinities to serotonin 5-HT1A,2A/2C receptors and muscarinic receptors. Results have shown that MK-801 disrupted PPI and increased the ASR in rats. Our results showed no effect of zotepine (1 and 2 mg/kg) and risperidone (0.1 and 1 mg/kg) on disrupted PPI by MK-801. Administration of clozapine (5 and 10 mg/kg) and olanzapine (2.5 and 5 mg/kg) restored the deficits in PPI induced by MK-801. Additionally, we found a decrease of approximately 46% in PPI after administration of clozapine (5 mg/kg) and olanzapine (2.5 and 5 mg/kg) without MK-801 treatment. In summary, the four "atypical" antipsychotics had different efficacies to restore the disrupted PPI by MK-801. Only clozapine and olanzapin restored the MK-801-induced deficits in PPI.

UI MeSH Term Description Entries
D008297 Male Males
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003988 Dibenzothiepins
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000077152 Olanzapine A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine,LY 170053,LY-170052,Olanzapine Pamoate,Zolafren,Zyprexa,LY 170052,LY170052
D000161 Acoustic Stimulation Use of sound to elicit a response in the nervous system. Auditory Stimulation,Stimulation, Acoustic,Stimulation, Auditory
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D013216 Reflex, Startle A complex involuntary response to an unexpected strong stimulus. The reaction involves physical movement away from the stimulus, MUSCLE CONTRACTION and limb flexion, BLINKING, and changes in HEART RATE, BLOOD PRESSURE, and RESPIRATION. Startle Reaction,Acoustic Startle Reflex,Reflex, Moro,Startle Response,Moro Reflex,Reaction, Startle,Reactions, Startle,Reflex, Acoustic Startle,Response, Startle,Responses, Startle,Startle Reactions,Startle Reflex,Startle Reflex, Acoustic,Startle Responses

Related Publications

Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
January 1994, Journal of neural transmission. General section,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
July 1996, Schizophrenia research,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
January 1993, Psychopharmacology,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
October 2002, Schizophrenia research,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
January 1998, Progress in neuro-psychopharmacology & biological psychiatry,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
October 2011, Pharmacology, biochemistry, and behavior,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
October 2008, Psychopharmacology,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
January 2012, Arzneimittel-Forschung,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
July 2015, Neuroscience,
Vera Bubeníková, and Martin Votava, and Jirí Horácek, and Tomás Pálenícek, and Colleen Dockery
January 2016, Frontiers in cellular neuroscience,
Copied contents to your clipboard!